

# Table of Contents

Preface — V

Contributing authors — VII

## **1 Mesenchymal stem cells in the context of stem cell biology — 1**

- 1.1 Introduction – Definitions — 1
- 1.2 Embryonic and adult tissue stem cells — 2
- 1.3 Adult tissue stem cells and progenitors — 3
- 1.4 Adult stem cells and tissue homeostasis — 5
- 1.5 Adult stem cell niches — 5
- 1.6 Commitment and differentiation — 7
- 1.7 The case for bone marrow MSCs — 8
- 1.8 Clinical prospects — 10
- 1.9 Concluding remark — 11
- References — 11

## **2 Are mesenchymal stem cells immune privileged? — 17**

- 2.1 Introduction – Definition of mesenchymal stem cells (MSCs) — 17
- 2.2 The immunosuppressive effect of MSCs on immune cells — 18
- 2.3 The potential clinical benefits of MSCs as immunosuppressants — 20
- 2.4 The mechanisms of immunosuppression by MSCs — 21
- 2.5 The mechanisms of immunosuppression by human MSCs — 21
- 2.6 Immunosuppression by murine MSCs and the species difference underlying the mechanisms of immunosuppression by MSCs — 25
- 2.7 Immunosuppression mediated by fibroblasts — 28
- 2.8 The mechanisms of the immunosuppressive effect of MSCs are shared with other nonstromal cells — 28
- 2.9 How long can MSCs survive *in vivo*? — 28
- 2.10 Conclusion and discussion — 29
- References — 31

## **3 Mesenchymal stem cell therapies for autoimmune diseases — 37**

- 3.1 Introduction — 37
- 3.2 Autoimmune disease — 39
- 3.3 Mesenchymal stem cells (MSCs) — 41
  - 3.3.1 Animal models — 42
- 3.4 Results of MSCs clinical trials — 44
- 3.5 Safety of MSCs — 45
- 3.6 Conclusion — 45
- References — 46

<b>4</b>	<b>Mesenchymal stem cells in osteoarthritis and rheumatic disease — 51</b>
4.1	Introduction – Rheumatic diseases — 51
4.2	Rheumatoid arthritis (RA) — 51
4.3	Osteoarthritis (OA) — 53
4.4	MSCs in healthy and rheumatic joint tissues — 55
4.5	Application of MSCs in rheumatic diseases — 56
4.6	MSCs application in animals — 60
4.7	Clinical studies in humans — 66
4.8	Risks and benefits of MSCs treatments in rheumatic diseases — 68
	References — 70
<b>5</b>	<b>Mesenchymal stem cells in enthesis formation and repair — 83</b>
5.1	Introduction — 83
5.2	Structure of the tendon-to-bone junction — 84
5.3	Enthesis resident T cells are involved in enthesopathies provoking inflammation and bone remodeling — 85
5.4	Biomaterials and growth factor-dependent regeneration of tendon-to-bone junctions — 87
5.5	Biomechanical stimulation for enthesis repair — 88
5.6	Mesenchymal stem cells (MSCs) — 88
5.7	Stem cell-dependent approaches for repair of osteotendinous junctions — 89
5.8	Stem cell-dependent delivery of growth factors — 91
5.9	Stem cell-dependent delivery of tenogenic transcription factors — 93
5.10	Stem cell-dependent delivery of matrix metalloproteinases — 94
5.11	Trophic activities of MSCs in enthesis repair — 94
5.12	Outlook — 95
	Acknowledgment — 96
	References — 96
<b>6</b>	<b>Mesenchymal stem cells for clinical/therapeutic interventions of graft-versus-host disease — 101</b>
6.1	Clinical graft-versus-host disease — 101
6.2	Chronic graft-versus-host disease — 102
6.3	Rationale to use mesenchymal stromal cells for treatment of GvHD — 103
6.4	Experience of MSCs in clinical acute graft-versus-host disease — 105
6.5	Treatment of acute GvHD with stromal cells from alternate sources, adipose tissue-derived, umbilical cord blood-derived or fetal membrane-derived stromal cells — 110
6.6	Mesenchymal stromal cells for treatment of chronic graft-versus-host disease — 111

6.7	Clinical trials of prophylaxis with mesenchymal stromal cells for graft-versus-host disease — <b>113</b>
6.8	Discussion on clinical use of mesenchymal stem cells — <b>115</b>
6.9	How should we best utilize MSC treatment of GvHD? — <b>116</b>
	References — <b>119</b>
<b>7</b>	<b>Mesenchymal stem cells for graft-versus-host disease in experimental animal models — 125</b>
7.1	Introduction – Experimental models of graft-versus-host disease (GvHD) — <b>125</b>
7.2	Immunobiology of experimental GvHD — <b>127</b>
7.3	Mesenchymal stromal cells in mice — <b>128</b>
7.4	Mesenchymal stromal cells and mouse models of graft-versus-host disease — <b>130</b>
	References — <b>136</b>
<b>8</b>	<b>Mesenchymal stem cells and organ transplantation: initial clinical results — 143</b>
8.1	Introduction — <b>143</b>
8.2	Rationale for the use of MSCs in organ transplantation — <b>144</b>
8.2.1	Shortage of donor organs for transplantation — <b>144</b>
8.2.2	Ischemia-reperfusion injury — <b>145</b>
8.2.3	Chronic immunosuppression — <b>145</b>
8.3	Considerations regarding the choice of the clinical protocols — <b>146</b>
8.3.1	Definition, identity and product release criteria for human MSCs preparations — <b>147</b>
8.3.2	Source of human MSCs — <b>147</b>
8.3.3	Potential interactions between MSCs and concomitant therapy — <b>149</b>
8.3.4	Safety of MSCs-based treatments — <b>150</b>
8.4	Clinical MSCs and solid organ transplantation trials — <b>151</b>
8.4.1	Autologous MSCs in the induction phase with standard immunosuppression — <b>151</b>
8.4.2	Autologous MSCs in the induction phase with avoidance of biologics at induction and reduced maintenance immunosuppression — <b>154</b>
8.4.3	Allogeneic MSCs in the induction phase — <b>155</b>
8.4.4	Autologous MSCs for the treatment of biopsy-proven subclinical rejection, progressive renal interstitial fibrosis and tubular atrophy — <b>156</b>
8.5	Future perspectives — <b>158</b>
	Acknowledgments: — <b>158</b>
	References — <b>159</b>

<b>9</b>	<b>Stem cell therapy in patients with ischemic heart disease — 163</b>
9.1	Introduction — <b>163</b>
9.2	Cell type and source for clinical therapy — <b>165</b>
9.3	Mechanisms behind regeneration of damaged myocardium — <b>166</b>
9.4	Preclinical experience with stem cells for IHD — <b>169</b>
9.5	Cell-based therapy in patients with IHD — <b>169</b>
9.6	MSCs in patients with IHD — <b>171</b>
9.7	Ongoing clinical trials using MSCs — <b>174</b>
9.8	Cell delivery and engraftment — <b>174</b>
9.9	Perspectives — <b>178</b>
9.10	Conclusion — <b>179</b>
	References — <b>179</b>
<b>10</b>	<b>Mesenchymal stem cells as a strategy for the treatment of multiple sclerosis and other diseases of the central nervous system — 185</b>
10.1	Introduction — <b>185</b>
10.2	MSCs transplantation for neurological diseases: why, which, and how — <b>186</b>
10.3	Vascular diseases: ischemic stroke — <b>187</b>
10.3.1	Preclinical studies — <b>187</b>
10.3.2	Clinical studies — <b>189</b>
10.4	Trauma spinal cord injury — <b>190</b>
10.4.1	Preclinical studies — <b>191</b>
10.4.2	Clinical studies — <b>192</b>
10.5	Extrapyramidal diseases — <b>192</b>
10.5.1	Parkinson's disease (PD) — <b>192</b>
10.5.2	Preclinical studies — <b>193</b>
10.5.3	Clinical studies — <b>194</b>
10.5.4	Huntington's disease (HD) — <b>194</b>
10.5.5	Preclinical studies — <b>195</b>
10.6	Multiple system atrophy (MSA) — <b>196</b>
10.6.1	Preclinical studies — <b>196</b>
10.6.2	Clinical studies — <b>197</b>
10.7	CNS demyelinating diseases: multiple sclerosis — <b>197</b>
10.7.1	Preclinical studies — <b>198</b>
10.7.2	Clinical studies — <b>199</b>
10.8	Motor neuron diseases: amyotrophic lateral sclerosis (ALS) — <b>200</b>
10.8.1	Preclinical studies — <b>200</b>
10.8.2	Clinical studies — <b>201</b>
10.9	Dementia: Alzheimer's disease (AD) — <b>202</b>
10.9.1	Preclinical studies — <b>202</b>

10.9.2	Clinical studies —	203
10.10	Concluding remarks —	203
	References —	204
<b>11</b>	<b>Mesenchymal stem cells for the treatment of inflammatory bowel disease —</b>	<b>211</b>
11.1	Introduction —	211
11.2	Immunology and intestinal barrier function —	212
11.3	Cell-based treatments for IBD —	215
11.3.1	Hematopoietic cell transplantation —	215
11.4	T regulatory cells (Tregs) —	216
11.5	Mesenchymal stem cells (MSCs) —	217
11.5.1	Immunologic basis for MSCs and IBD —	217
11.6	MSC homing and engraftment —	219
11.7	MSC clinical trials —	222
11.8	Summary and future directions —	224
	References —	226
<b>12</b>	<b>Mesenchymal stem cells in chronic lung diseases: COPD and lung fibrosis —</b>	<b>233</b>
12.1	Introduction —	233
12.2	Idiopathic pulmonary fibrosis —	235
12.3	MSCs and animal models of fibrotic lung disorders —	238
12.4	Chronic obstructive pulmonary disease (COPD) —	246
12.5	Conclusions and future directions —	252
	Acknowledgments —	253
	References —	253
<b>13</b>	<b>Mesenchymal stem cells as therapeutics for liver repair and regeneration —</b>	<b>263</b>
13.1	Introduction —	263
13.2	Cell therapy for liver disease —	264
13.3	The ideal cell for liver regeneration —	265
13.4	Mesenchymal stem cells (MSCs) as cellular therapeutics —	266
13.5	MSCs for treating liver disease —	269
13.5.1	In vitro models to study MSCs hepatic differentiation —	269
13.5.2	In vivo models to study MSCs as cellular therapies for liver disease/ injury —	270
13.6	The fetal sheep model —	273
13.7	Clinical trials using MSCs for liver regeneration —	279
13.8	Summary/Conclusions: —	280
	References —	281

<b>14</b>	<b>Mesenchymal stem cells attenuate renal fibrosis — 293</b>
14.1	Introduction – Kidney function — 293
14.2	Kidney dysfunction and chronic kidney disease (CDK) — 295
14.2.1	Molecular and cellular interaction in renal fibrosis — 296
14.3	Mesenchymal stem cells (MSCs): Definition and basic features — 298
14.3.1	Therapeutic potential of MSCs and their mechanisms of action in the repair/ regeneration of tissue injury — 298
14.4	MSCs and kidney diseases — 301
14.4.1	MSCs have a prominent antifibrotic effect in distinct models of experimental chronic kidney diseases — 301
14.4.2	Mechanisms related to MSCs prevent renal fibrosis — 303
14.5	Final considerations — 304
	References — 305
<b>15</b>	<b>Immunomodulation by mesenchymal stem cells – a potential therapeutic strategy for type 1 diabetes — 309</b>
15.1	Introduction — 309
15.2	Mechanisms of immunomodulation — 310
15.3	MSC therapy for type 1 diabetes (T1D) — 311
15.3.1	Why does MSC therapy hold value in T1D? — 311
15.3.2	Preclinical studies to prevent and reverse T1D — 312
15.3.3	MSC implications in islet cell transplantation — 313
15.3.4	MSCs and clinical trials for T1D — 314
15.4	Safety of MSC therapy — 315
	References: — 315
<b>16</b>	<b>Fibrogenic potential of human multipotent mesenchymal stem cells in inflammatory environments — 319</b>
16.1	Introduction — 319
16.2	Fibrogenic potential in <i>ex vivo</i> expanded MSCs — 320
16.3	Evidence of MSCs infiltration into tumor stroma — 321
16.4	Controversies regarding therapeutic benefits of bone marrow-derived MSCs in liver fibrosis — 322
16.5	Limited contribution of MSCs to liver regeneration in acute liver injury — 324
16.6	Conclusion — 326
	References — 326

<b>17</b>	<b>Mesenchymal stem cells and the tumor microenvironment — 331</b>
17.1	Introduction — 331
17.2	The tumor microenvironment and its role in cancer initiation and progression — 333
17.3	How do we define MSCs in cancer? — 334
17.4	What are the roles of MSCs in cancer progression? — 335
17.4.1	Effect of MSCs on tumor cell proliferation — 337
17.4.2	MSCs promote survival — 337
17.4.3	MSCs are proangiogenic — 338
17.4.4	MSCs have an immunosuppressive function — 338
17.4.5	MSCs promote epithelial to mesenchymal transition — 339
17.5	How do tumor cells communicate with MSCs? — 341
17.6	Are MSCs recruited by tumor cells? — 343
17.7	Can we target MSCs in human cancer? — 345
17.8	Conclusion — 346
	References — 346
<b>18</b>	<b>Mesenchymal stem cells as a carrier for tumor-targeting therapeutics — 353</b>
18.1	Introduction — 353
18.2	Enhanced angiogenesis as a target for tumor therapy — 354
18.3	Why current therapies are not effective enough — 355
18.3.1	Shortcomings of current anti-angiogenic pharmaceuticals — 356
18.4	Why mesenchymal stem cells would be useful for tumor targeting — 358
18.4.1	The tumor-homing properties of MSCs — 358
18.4.2	MSCs as a diagnostic tool — 361
18.4.3	Antitumor effects of unmanipulated MSCs — 361
18.4.4	Vesicular communication of MSCs: How MSCs can be used as a drug-delivery vehicle — 362
18.5	MSCs as a gene product-delivering vehicle — 364
18.5.1	Genetically modified MSCs for therapeutic delivery — 364
18.5.2	Potential for MSCs-delivered anti-angiogenic therapies — 365
18.5.3	MSCs-mediated tumor-homing of oncolytic adenovirus enhances tumor therapy — 366
18.5.4	Delivery of TRAIL by genetically modified MSCs to induce apoptosis — 367
18.5.5	Tumor-specific promoter-driving thymidine kinase (TK) expression for prodrug conversion — 367
18.6	Methods of therapeutic MSCs administration — 369
18.7	The advantage of MSCs being immunoprivileged — 370
18.8	Sources of acquiring MSCs for tumor therapy — 371

18.9	Remaining challenges for the use of MSCs to deliver therapeutics —	372
18.9.1	The immunoprivileged nature of MSCs —	372
18.9.2	Varying responses to MSCs depending on cancer type, injection site, etc. —	372
18.9.3	Changes in MSCs induced by cancer cells within the tumor microenvironment —	373
18.10	Summary and prospective —	375
	Acknowledgments —	375
	References —	376
<b>19</b>	<b>Systems biology approach to stem cells, tissues and inflammation —</b>	<b>381</b>
19.1	Introduction —	381
19.2	Biological aspects —	382
19.2.1	Cells are the regulatory units —	382
19.2.2	Influence of cell number and phenotype —	383
19.3	Technological aspects —	383
19.3.1	Technology and type of molecules —	383
19.3.2	When “pictures start moving” —	384
19.4	Mathematical aspects —	385
19.4.1	Comparative statistics and interpretation —	385
19.4.2	Interpretation based on pre-existing knowledge —	386
19.4.3	Network models —	386
19.5	Systems biology of differentiation —	388
19.6	Important tasks —	389
19.7	Conclusion —	390
	References —	391

<b>Index —</b>	<b>395</b>
----------------	------------